To encourage more networking within interest sections, during the 2025 AAAAI / WAO Joint Congress, February 28 – March 3 in San Diego, CA, USA, Interest Section Forums will be changing to “Get to Know Your Interest Section” sessions.
The speaker presentations usually held during Interest Section Forums are now pre-recorded talks. These talks are an excellent way to learn something new and get a better understanding of each interest section’s goals. You can find all the pre-recorded talks below.
To learn more about the AAAAI’s interest sections and how you can get involved, click here.
Anaphylaxis, Dermatology & Drug Allergy (ADDA)We welcome you to join the Anaphylaxis Dermatology and Drug Allergy (ADDA) interest section. We cover so much of clinical allergy and immunology: anaphylaxis, urticaria, angioedema, atopic dermatitis, allergic contact dermatitis, and drug allergy.
| Asthma Diagnosis & Treatment (ADT)In these videos, Dr. Alan Baptist and Dr. Karla Adams discuss two important topics. In the first, Dr. Baptist discusses implementation challenges around inhaler therapy – including SMART and AIR therapy. In the second, Dr. Adams discusses important work being done in the ADT Interest section |
Basic and Clinical Immunology (BCI)Welcome to the Basic and Clinical Immunology (BCI) Interest Section! This interest section’s focus are the mechanisms of Immunology, immune mediated disease and practical clinical applications. We invited you to listen to Dr. Liana Falcone talk about the immune pathogenesis that occurs in post-acute COVID. Additionally, Dr. Falcone discusses the involvement of the gut microbiome in this post-viral syndrome and its role in abnormal immune function as well as the clinical implications of COVID induced immune dysregulation and symptom manifestation. Dr. Falcone's presentation focuses on many important areas of interest in BCI regarding immune dysregulation and impacts on immune competence leading immunodeficiency, autoinflammatory and autoimmune conditions. This work importantly highlights the immunopathology and the role if disease prevention through vaccination. The BCI’s exciting work and professional growth opportunities happen in our committees! Join one of our committees: Autoimmunity and Altered Immune Response (Chair: Jolan Walter), Genetics, Molecular Biology and Epidemiology (Chair: Sarah Henrickson), Primary Immunodeficiency Diseases (Chair: Jennifer Heimall), and Vaccines (Chair: Karla Adams). | Food Allergy & Eosinophilic Disorders (FAED)Dear members of the Food Allergy and Eosinophilic Diseases (FAED) Interest Section, We are thrilled to be in the final stages of preparation for the 2025 AAAAI Annual Scientific Meeting in a time when we have two FDA-approved treatments for food allergy; two FDA-approved treatments for eosinophilic esophagitis; and a new FDA-approved route of epinephrine administration to complement the growing market of epinephrine autoinjectors available to our patients. These novel therapies could never have made it to market without the heroic efforts of stakeholders across the country, including numerous members of FAED. As we look toward a future when a full complement of treatment options is available to our patients for food allergy and eosinophilic esophagitis, we should take a moment to appreciate the work that so many AAAAI members done to make a reality what once seemed like an impossibility. In this video, past Chair of the Adverse Reactions to Foods Committee and an internationally recognized leader in the development of novel therapies for IgE mediated food allergy, Dr. David Fleischer explains how two immunotherapies, oral immunotherapy and biologic therapy, can be integrated into the care that we provide our patients with food allergy. Through a review of the scientific literature, he proposes methods to balance safety, efficacy, and practicality in the treatment choices we make in partnership with those we treat. He considers populations that may benefit the most from immunotherapy, and those for whom one or more method of immunotherapy is contraindicated. Finally, Dr. Fleischer outlines key considerations as we look toward the next generation of food immunotherapy. Whether you are new a new member thinking about getting involved or a long-standing Fellow of the Academy, we invite you to join us at the annual meeting at one of the many FAED offerings, including: The Adverse Reactions to Foods Committee on 3/1/2025 at 6:30 – 8:00am Still not sure how to get involved? Please do not hesitate to reach out to us with questions. We look forward to seeing you in sunny San Diego in 2025. |
Health, Equity, Technology & Quality (HETQ)Please join us to learn more about the Health, Equity, Technology & Quality (HETQ) Interest Section and watch our new video on the innovative activities of the School-Based Allergy, Asthma and Anaphylaxis Management Program (SAMPRO). | Immunotherapy, Rhinitis, Sinusitis and Ocular Disease (IRSO)Subcutaneous immunotherapy (SCIT) and sublingual Immunotherapy (SLIT) are the most common treatments routinely used in clinical care to treat allergic rhinitis and improve many associated co-morbid conditions. This short video focuses on current knowledge about SCIT and SLIT dosing for aeroallergen, accelerated schedules for build-up, and adjustment for gaps in treatment. |
Mechanisms of Asthma and Allergic Inflammation (MAAI)Wildfire smoke exposure is becoming an increasing public health concern, especially for individuals with allergic diseases such as asthma and allergic rhinitis. We invited Professor Kari Nadeau on behalf of the Mechanisms of Asthma, Allergy, and Immunology Interest Section membership to talk about the mechanisms by which wildfire smoke exacerbates allergic responses and worsens respiratory health. Fine particulate matter (PM2.5), ozone (O3), and other toxic pollutants in wildfire smoke can trigger inflammation, disrupt the epithelial barrier, and activate immune pathways involved in allergic sensitization. Exposure to these pollutants has been linked to increased asthma exacerbations, reduced lung function, and enhanced allergic airway inflammation. Professor Nadeau highlights the latest findings on how wildfire smoke affects immune responses, including the role of epigenetics, oxidative stress and altered cytokine profiles, which can worsen pre-existing allergic conditions. Part of the mission of MAAI is to promote a deeper understanding of how environmental factors (such as wildfire smoke) contribute to allergic disease pathogenesis, particularly in vulnerable populations. Our goal with this insightful lecture by Professor Nadeau was to underscore the importance of environmental triggers in allergic diseases and inspire future strategies for research, mitigation and protection. |